PerkinElmer, Inc. (NYSE:PKI) has been given a $65.00 target price by research analysts at Cantor Fitzgerald in a research note issued on Monday. The firm currently has a “hold” rating on the medical research company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 2.25% from the stock’s current price.

A number of other equities analysts also recently commented on the company. Janney Montgomery Scott upgraded PerkinElmer from a “neutral” rating to a “buy” rating in a report on Monday, March 27th. Jefferies Group LLC restated a “hold” rating and set a $49.00 target price on shares of PerkinElmer in a report on Friday, May 5th. Zacks Investment Research upgraded PerkinElmer from a “sell” rating to a “hold” rating in a report on Friday, March 10th. Citigroup Inc. upped their target price on PerkinElmer from $57.00 to $67.00 and gave the company a “buy” rating in a report on Friday, April 7th. Finally, BidaskClub downgraded PerkinElmer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 14th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $57.30.

Analyst Recommendations for PerkinElmer (NYSE:PKI)

PerkinElmer (NYSE:PKI) traded up 5.624% on Monday, reaching $67.145. 1,641,340 shares of the company’s stock traded hands. The firm’s 50-day moving average is $62.63 and its 200 day moving average is $56.70. PerkinElmer has a 12 month low of $45.35 and a 12 month high of $67.67. The firm has a market cap of $7.39 billion, a PE ratio of 32.738 and a beta of 0.73.

PerkinElmer (NYSE:PKI) last announced its earnings results on Thursday, May 4th. The medical research company reported $0.55 EPS for the quarter, beating analysts’ consensus estimates of $0.54 by $0.01. The company had revenue of $514.12 million during the quarter, compared to the consensus estimate of $506.81 million. PerkinElmer had a return on equity of 13.97% and a net margin of 10.24%. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.50 earnings per share. Equities analysts predict that PerkinElmer will post $2.86 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, August 10th. Investors of record on Friday, July 21st will be paid a $0.07 dividend. The ex-dividend date is Wednesday, July 19th. This represents a $0.28 annualized dividend and a yield of 0.44%. PerkinElmer’s payout ratio is 13.66%.

COPYRIGHT VIOLATION WARNING: “PerkinElmer, Inc. (PKI) PT Set at $65.00 by Cantor Fitzgerald” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/06/19/perkinelmer-inc-pki-pt-set-at-65-00-by-cantor-fitzgerald.html.

In related news, Director Patrick J. Sullivan sold 6,628 shares of the company’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $62.59, for a total value of $414,846.52. Following the sale, the director now directly owns 42,951 shares of the company’s stock, valued at $2,688,303.09. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Peter Barrett sold 10,000 shares of the company’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $63.22, for a total value of $632,200.00. Following the completion of the sale, the director now directly owns 29,200 shares in the company, valued at $1,846,024. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 166,565 shares of company stock worth $10,056,999. 2.20% of the stock is owned by insiders.

A number of large investors have recently modified their holdings of PKI. Russell Investments Group Ltd. purchased a new stake in shares of PerkinElmer during the fourth quarter valued at $988,000. Bessemer Group Inc. boosted its stake in PerkinElmer by 86.9% in the fourth quarter. Bessemer Group Inc. now owns 14,370 shares of the medical research company’s stock worth $750,000 after buying an additional 6,680 shares in the last quarter. State Street Corp boosted its stake in PerkinElmer by 6.8% in the fourth quarter. State Street Corp now owns 3,792,638 shares of the medical research company’s stock worth $197,792,000 after buying an additional 241,465 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its stake in PerkinElmer by 0.5% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,280 shares of the medical research company’s stock worth $328,000 after buying an additional 32 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in PerkinElmer by 8.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 772,837 shares of the medical research company’s stock worth $40,304,000 after buying an additional 59,736 shares in the last quarter. 92.70% of the stock is currently owned by institutional investors.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.